We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

28 hedge funds and large institutions have $5.32M invested in Immix Biopharma in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

284% more capital invested

Capital invested by funds: $1.39M → $5.32M (+$3.93M)

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

75% more funds holding

Funds holding: 16 → 28 (+12)

1.88% more ownership

Funds ownership: 2.06% → 3.93% (+1.9%)

Holders
28
Holders Change
+12
Holders Change %
+75%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
7
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$465K
2
PAG
Private Advisor Group
New Jersey
+$452K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$245K
4
Renaissance Technologies
Renaissance Technologies
New York
+$147K
5
Northern Trust
Northern Trust
Illinois
+$110K

Top Sellers

Rank Fund Capital Flow
1
Koshinski Asset Management
Koshinski Asset Management
Illinois
-$174K
2
ICG
InterOcean Capital Group
Tennessee
-$18.1K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$2.51K
4
BlackRock
BlackRock
New York
-$1.26K

IMMX Hedge Fund Activity: Q4 2023 in Review

28 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q4 2023, worth a combined $5.32M — up 284% from $1.39M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IMMX positions and 1 closed out — a net gain of 12 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $465K. The largest seller was Koshinski Asset Management, exiting entirely with an estimated $174K sold.

  • 28 institutional investors held Immix Biopharma (IMMX) as of Q4 2023, up from 16 in Q3 2023.
  • Funds reported $5.32M of Immix Biopharma stock for Q4 2023, up 284% quarter-over-quarter.
  • 13 funds opened new Immix Biopharma positions in Q4 2023 and 1 closed out, a net change of +12 holders.
  • The largest Immix Biopharma buyer in Q4 2023 was EAM Investors, an estimated $465K added.
  • The largest Immix Biopharma seller in Q4 2023 was Koshinski Asset Management, an estimated $174K sold.

Based on aggregated 13F filings for Q4 2023.